Update 2016 – Immuntherapie beim Urothelkarzinom

Translated title of the contribution: Update 2016 – Immunotherapy for urothelial carcinoma

M. Retz, J. E. Gschwend, S. C. Schmid

Research output: Contribution to journalArticlepeer-review


Advanced urothelial carcinoma of the bladder is an aggressive tumor with a poor prognosis. Besides surgical therapy, classical chemotherapy with platinum compounds is the mainstay of advanced bladder cancer treatment. In recent years, immune modulating therapies have come into the focus of clinical trials. This review provides an overview of the biological mechanisms and immuno-oncological drugs that are currently being analyzed in clinical trials as well as established standard therapies.

Translated title of the contributionUpdate 2016 – Immunotherapy for urothelial carcinoma
Original languageGerman
Pages (from-to)246-252
Number of pages7
JournalUrologe - Ausgabe A
Issue number2
StatePublished - 1 Feb 2016
Externally publishedYes


Dive into the research topics of 'Update 2016 – Immunotherapy for urothelial carcinoma'. Together they form a unique fingerprint.

Cite this